Navigation Links
Biolex presents Locteron US Phase 2a hepatitis C data at EASL
Date:4/24/2009

Biolex Therapeutics, Inc. announced that the results from its United States Phase 2a clinical trial (the "PLUS" trial) of Locteron will be presented today at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark. Locteron, controlled-release interferon alpha 2b, is designed to improve patient care by providing a more convenient once-every-two week dosing schedule and by reducing the side effects, including flu-like symptoms, associated with pegylated interferons, the current standard of care. Biolex announced earlier this week the commencement of patient dosing in the SELECT-2, a Phase 2b trial of Locteron in the United States and Europe.

The PLUS Phase 2a clinical trial was conducted in 32 chronic hepatitis C patients in the United States who had failed prior treatment. The PLUS trial was designed to evaluate the safety and tolerability of Locteron, and to directly compare Locteron with pegylated interferon. Patients were randomized to receive either Locteron (administered once every two weeks) or PEG-Intron (administered once per week). The Locteron doses evaluated in the PLUS trial include 320 μg, the lowest dose to be evaluated in the SELECT-2 trial, and 640 μg, the highest dose of Locteron evaluated to date. All patients also received oral, weight-based ribavirin. Patients were treated for four weeks with an additional two weeks of follow up evaluation.

Flu-like symptoms were reported to be less frequent and milder in both of the Locteron cohorts of the PLUS trial. The total severity score for flu-like symptoms for patients in the 320 g cohort of Locteron was 80 percent lower than the severity score for the PEG-Intron control cohort (severity score was based on number of occurrences adjusted for severity rating of adverse event). The total severity score for patients in the 640 g cohort of Locteron was 30 percent lower than the severity score for the PEG-Intron cohort.
'/>"/>

Contact: Michelle Linn
linnmich@comcast.net
508-362-3087
Linnden Communications
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. GSA special paper presents new studies of Western US earth motion
2. AIUM Presents 2009 Joseph H. Holmes Pioneer Awards
3. AIUM presents 2009 Memorial Hall of Fame awards
4. AIUM presents 2009 Distinguished Sonographer award
5. AIUM presents 2009 William J. Fry Memorial Lecture award
6. Stevens Center for Science Writings presents: Ravens at the Feast, with Bernd Heinrich, April 1
7. Understanding soil carbon sequestration: New book presents key concepts
8. World Congress on Osteoporosis 2010 presents outstanding scientific program
9. New manual presents robust, state-of-the-art proteomics methods for teaching and research
10. Arbor Vita presents new data on cancer diagnostic at EUrogin
11. Soil Science Society of America presents awards in Houston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2014)... and pancreatic cancers also promote drug-resistance and ultimately spur ... Diego School of Medicine have discovered a molecule, or ... that appears responsible for inducing tumor metastasis by enhancing ... The findings, published in the April 20, 2014 online ... to new therapeutic opportunities for reversing drug resistance in ...
(Date:4/18/2014)... in Peru found that 28 percent of the ... falsified. Many pills released the active ingredient too ... batch had no active ingredient at all. ... the Georgia Institute of Technology developed a sophisticated ... counterfeit drugs and then characterize their chemical composition. ...
(Date:4/18/2014)... NC Ancient DNA adds a twist to the story ... to be published April 21 in the journal Proceedings ... from the bones of chickens that lived 200-2300 years ago ... ago domestic chickens may have looked far different from the ... of the traits we associate with modern domestic chickens -- ...
Breaking Biology News(10 mins):Cancer stem cells linked to drug resistance 2Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Ancient DNA offers clues to how barnyard chickens came to be 2
... Jianmin Cui was handed a puzzling clue to the structure ... five years. Scientists at the Cleveland Clinic Foundation in ... epilepsy, sudden attacks of involuntary movement or both, a syndrome ... the DNA of the 16 family members who had inherited ...
... are fostering development of a new generation of vaccines, ... potentially deadly bacteria in any future bioterrorist incident. That,s ... on medical technology to combat the anthrax threat. It ... . In the article, Dimitrios Bouzianas notes ...
... Scientists are reporting that particle size affects the toxicity ... smaller than 100 nanometers are slightly more toxic to colon ... toxic than equivalent amounts of soluble zinc, and direct particle ... study is in ACS, Chemical Research in Toxicology , ...
Cached Biology News:Solving the puzzle of the BK ion channel 2Solving the puzzle of the BK ion channel 3Solving the puzzle of the BK ion channel 4Solving the puzzle of the BK ion channel 5New medical weapons to protect against anthrax attacks 2
(Date:1/15/2014)... Freeslate, Inc ., the leading provider ... Limited, one of India’s top five pharmaceutical companies, has ... for high throughput solid form screening. , ... wide range of quality, affordable generic and branded formulations ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have ... at 2pm EST (11am PST), “Natural Language Processing: Converting ... how technology can turn raw, heterogeneous data into actionable ... The online webinar will last approximately one hour. , ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... , , HONG KONG, Dec. 31 /PRNewswire-Asia-FirstCall/ ... CO ), China,s leading provider of cord blood ... storage services, today announced that the underwriters of its recent ... their over-allotment option, which will result in the issuance of ...
... NORTH BILLERICA, Mass., Dec. 29 Seahorse Bioscience, Inc., leader ... bioenergetics, announced that TheScientist magazine cited their XF96 ... A panel of scientific experts assembled by TheScientist ... the two energy pathways of the cell in a microplate, ...
... , EMERYVILLE, Calif., Dec. 29 ... of results from its study on the anti-tumor mechanism of ... International Journal of Cancer , describe the potential molecular ... BN107 on estrogen receptor negative (ER-) breast cancer cells. , ...
Cached Biology Technology:China Cord Blood Corporation Announces Partial Exercise of Over-Allotment Option 2China Cord Blood Corporation Announces Partial Exercise of Over-Allotment Option 3TheScientist Awards Seahorse XF96 Analyzer a Top Ten Innovation for 2009 2Bionovo Announces Publication Describing First Novel Dual mTOR Inhibitor, BN107, for the Treatment of Breast Cancer 2Bionovo Announces Publication Describing First Novel Dual mTOR Inhibitor, BN107, for the Treatment of Breast Cancer 3
... for your specific applications and built on ... platform. Thousands of customer specified sequences can ... provide assistance with custom sequence design. These ... comprehensive Custom DNA Microarray Service. ...
... designed for DNA aptamer screening and binding ... powerful Paraflo microfluidic on-chip synthesis platform. These ... comprehensive DNA/RNA Aptamer Microarray Service. ... Microarray contains greater than 1500 known aptamer ...
... for DNA aptamer screening and binding optimization ... Paraflo microfluidic on-chip synthesis platform. Thousands of ... and LC Sciences can provide assistance with ... as part of our comprehensive DNA/RNA Aptamer ...
... (GST) is commonly used as a fusion ... (1). The GSTTag sequence has been reported ... cases the solubility of its fusion partners. ... form, GSTTag fusion proteins can be purified ...
Biology Products: